| 郑迎春,李 真,王 悦,曲延文,王俊杰.紫杉醇+卡铂化疗方案联合放疗对高危子宫内膜癌患者血清肿瘤标志物、Th1/Th2型细胞因子及癌基因表达的影响[J].现代生物医学进展英文版,2023,(16):3154-3158. |
| 紫杉醇+卡铂化疗方案联合放疗对高危子宫内膜癌患者血清肿瘤标志物、Th1/Th2型细胞因子及癌基因表达的影响 |
| Effects of Paclitaxel Plus Carboplatin Chemotherapy Regimen Combined with Radiotherapy on Serum Tumor Markers, Th1/Th2 Cytokines and Oncogene Expression in High-Risk Endometrial Cancer Patients |
| Received:December 07, 2022 Revised:December 31, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.16.030 |
| 中文关键词: 紫杉醇 卡铂 放疗 子宫内膜癌 肿瘤标志物 Th1/Th2 癌基因 |
| 英文关键词: Paclitaxel Carboplatin Radiotherapy Endometrial cancer Tumor markers Th1/Th2 Oncogene |
| 基金项目:山东省科技创新工程专项课题项目（2018SDKJ0404-3） |
|
| Hits: 434 |
| Download times: 373 |
| 中文摘要: |
| 摘要 目的：探讨紫杉醇+卡铂化疗方案联合放疗对高危子宫内膜癌（EC）患者血清肿瘤标志物、辅助性T细胞（Th）1/Th2型细胞因子及癌基因表达的影响。方法：选取我院2018年4月~2019年2月期间收治的80例高危EC患者作为研究对象，按照随机数字表法分为对照组（n=40）和研究组（n=40），在常规治疗的基础上，对照组接受紫杉醇+卡铂化疗方案，研究组在对照组的基础上结合放疗。观察两组治疗后的客观缓解率和疾病控制率，对比两组血清肿瘤标志物、Th1/Th2型细胞因子水平及癌基因表达的变化情况，记录两组不良反应发生率、3年肿瘤复发率及淋巴结转移率。结果：研究组的客观缓解率、疾病控制率高于对照组（P<0.05）。治疗后，两组甲壳质酶蛋白40（YKL-40）、人附睾蛋白4（HE4）、细胞角蛋白-19片段（CYFRA21-1）、癌胚抗原（CEA）均下降，且研究组的下降程度大于对照组（P<0.05）。治疗后，两组白介素-4（IL-4）下降，γ-干扰素（IFN-γ）、IFN-γ/IL-4升高，且研究组的改善程度大于对照组（P<0.05）。治疗后，两组c-erbB2、c-myc下降，P53、P16升高，且研究组的改善程度大于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。研究组的3年肿瘤复发率、淋巴结转移率低于对照组（P<0.05）。结论：紫杉醇+卡铂化疗方案联合放疗用于高危EC患者，可调节免疫平衡、癌基因表达，降低血清肿瘤标志物水平，从而提高临床疗效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of paclitaxel plus carboplatin chemotherapy combined with radiotherapy on serum tumor markers, T helper cell (Th) 1/Th2 cytokines and oncogene expression in high-risk endometrial cancer (EC) patients. Methods: 80 cases of high-risk EC patients who were admitted to our hospital from April 2018 to February 2019 were selected as research objects, and they were randomly divided into the control group (n=40) and the study group (n=40) according to the method of random number table. On the basis of conventional treatment, the control group received paclitaxel plus carboplatin chemotherapy, while the study group received radiotherapy on the basis of the control group. The objective remission rate and disease control rate after treatment were observed in the two groups. The changes of serum tumor markers, Th1/Th2 cytokine levels and oncogene expression in the two groups were compared. The incidence rate of adverse reactions, 3-year tumor recurrence rate and lymph node metastasis rate in the two groups were recorded. Results: The objective remission rate and disease control rate in the study group were higher than those in the control group (P<0.05). After treatment, the chitinase protein 40 (YKL-40), human epididymal protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) in the two groups decreased, and the degree of decline in the study group was greater than that in the control group(P<0.05). After treatment, the interleukin-4(IL-4) in the two groups decreased, and interferon-γ(IFN-γ) and IFN-γ/IL-4 increased, and the improvement degree in the study group was greater than that in the control group (P<0.05). After treatment, the c-erbB2 and c-myc in the two groups decreased, P53 and P16 increased, and the improvement degree in the study group was greater than that in the control group (P<0.05). There was no difference in the incidence rate of adverse reactions in the two groups (P>0.05). The 3-year tumor recurrence rate and lymph node metastasis rate in the study group were lower than those in the control group (P<0.05). Conclusion: Paclitaxel plus carboplatin chemotherapy combined with radiotherapy for high-risk EC patients can regulate immune balance, oncogene expression, reduce serum tumor marker levels, so as to improve clinical efficacy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
